GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Corcept Therapeutics Inc (NAS:CORT) » Definitions » 3-Year EPS without NRI Growth Rate

Corcept Therapeutics (Corcept Therapeutics) 3-Year EPS without NRI Growth Rate : 3.40% (As of Dec. 2023)


View and export this data going back to 2004. Start your Free Trial

What is Corcept Therapeutics 3-Year EPS without NRI Growth Rate?

Corcept Therapeutics's EPS without NRI for the three months ended in Dec. 2023 was $0.28.

During the past 12 months, Corcept Therapeutics's average EPS without NRI Growth Rate was 8.00% per year. During the past 3 years, the average EPS without NRI Growth Rate was 3.40% per year. During the past 5 years, the average EPS without NRI Growth Rate was 7.90% per year. Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.

During the past 13 years, the highest 3-Year average EPS without NRI Growth Rate of Corcept Therapeutics was 210.70% per year. The lowest was -6.50% per year. And the median was 14.00% per year.


Competitive Comparison of Corcept Therapeutics's 3-Year EPS without NRI Growth Rate

For the Biotechnology subindustry, Corcept Therapeutics's 3-Year EPS without NRI Growth Rate, along with its competitors' market caps and 3-Year EPS without NRI Growth Rate data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Corcept Therapeutics's 3-Year EPS without NRI Growth Rate Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Corcept Therapeutics's 3-Year EPS without NRI Growth Rate distribution charts can be found below:

* The bar in red indicates where Corcept Therapeutics's 3-Year EPS without NRI Growth Rate falls into.



Corcept Therapeutics 3-Year EPS without NRI Growth Rate Calculation

This is the 3-year average growth rate of EPS without NRI. The growth rate is calculated using exponential compounding based on the latest four year annual data.

Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EPS without NRI growth rate.


Corcept Therapeutics  (NAS:CORT) 3-Year EPS without NRI Growth Rate Explanation

EPS without NRI is the amount of earnings without non-recurring items per outstanding share of the company's stock.

Earnings Per Share (EPS) is the single most important variable used by Wall Street in determining the earnings power of a company. But investors need to be aware that Earnings per Share can be easily manipulated by adjusting depreciation and amortization rate or non-recurring items. That's why GuruFocus lists Earnings per share without Non-Recurring Items, which better reflects the company's underlying performance.


Corcept Therapeutics 3-Year EPS without NRI Growth Rate Related Terms

Thank you for viewing the detailed overview of Corcept Therapeutics's 3-Year EPS without NRI Growth Rate provided by GuruFocus.com. Please click on the following links to see related term pages.


Corcept Therapeutics (Corcept Therapeutics) Business Description

Industry
Traded in Other Exchanges
Address
149 Commonwealth Drive, Menlo Park, CA, USA, 94025
Corcept Therapeutics Inc is a commercial-stage pharmaceutical company engaged in the discovery and development of medications that treat severe metabolic, oncologic and neuropsychiatric disorders by modulating the effect of the hormone cortisol.
Executives
Swisher Daniel N Jr director C/O SUNESIS PHARMACEUTICALS, INC., 395 OYSTER POINT BLVD., SUITE 400, SOUTH SAN FRANCISCO CA 94080
William Guyer officer: Chief Development Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gary Charles Robb officer: CHIEF FINANCIAL OFFICER C/O 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph Douglas Lyon officer: Chief Accounting Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Sean Maduck officer: See Remarks C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
David L Mahoney director SYMANTEC CORPORATION, 20330 STEVENS CREEK BLVD., CUPERTINO CA 95014
Hazel Hunt officer: Chief Scientific Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Joseph K Belanoff director, officer: CHIEF EXECUTIVE OFFICER 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Baker G Leonard Jr director, 10 percent owner 755 PAGE MILL ROAD, SUITE A-200, PALO ALTO CA 94304-1005
Joshua M. Murray director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Atabak Mokari officer: Chief Financial Officer 1212 TERRA BELLA AVENUE, MOUNTAIN VIEW CA 94043
Gillian Cannon director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Gregg H Alton director 333 LAKESIDE DRIVE, FOSTER CITY CA 94404
Kimberly Park director C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025
Andreas Grauer officer: Chief Medical Officer C/O CORCEPT THERAPEUTICS INCORPORATED, 149 COMMONWEALTH DRIVE, MENLO PARK CA 94025